Advertise
Resources
Member, Beacon International Group, Ltd.
Medicare will cover the controversial Alzheimer's drug Aduhelm but it will limit it to patients who enroll in clinical studies, officials with the Centers for Medicare and Medicaid announced April 7, Axios reports. The drug has been at the center of a fierce battle between patient groups and members of Congress pushing for access, and members of the medical community questioning the lack of evidence supporting the costly drug's safety and efficacy.